动脉静脉炎:发生率,病理生理学和治疗选择
Claudio Bianchini Massoni1, Laura Pauletti2, Antonio Freyrie2
1Vascular Surgery, Cardio-Thoracic and Vascular Department, University Hospital of Parma, 43126 Parma, Italy.
Journal of personalized medicine
|February 26, 2026
概括
动脉手术后的静脉炎是一种严重的并发症,由炎症和系统性风险因素 (如高血压和糖尿病) 驱动. 考虑到患者和斑块特征的个性化管理对于有效治疗至关重要.
科学领域:
- 血管外科 血管外科
- 干预心脏病学 干预心脏病学
- 心血管疾病 心血管疾病
背景情况:
- 静脉缩是心动脉内关节切除术和心动脉狭窄的支架后的主要并发症.
- 在外科手术和内血管治疗中,2年复缩率在6-12%之间.
- 复杂的炎症过程是早期和晚期复原的基础.
研究的目的:
- 审查心血管再血管化术后的静脉缩的原因和治疗方法.
- 确定导致复的关键系统性风险因素.
- 讨论当前的非程序和程序治疗策略.
主要方法:
- 关于治疗动脉狭窄和恢复狭窄的研究文献综述.
- 分析病因因素,包括炎症和全身风险.
- 评估非程序性 (生活方式,医疗疗) 和程序性 (手术,内血管) 干预措施.
主要成果:
- 系统性风险因素包括女性性别,高血压,糖尿病,脂质失调和吸烟.
- 非程序性管理涉及生活方式的改变和最佳的医疗治疗.
- 程序管理,主要是针对症状患者,包括各种开放式和内血管技术.
结论:
- 动脉干预后的静脉炎症是一个复杂的问题,受炎症和患者特定因素的影响.
- 有效的管理需要个性化的方法,整合患者的特征,斑块特征和治疗方式.
- 解决系统性风险因素和优化医疗治疗是护理的重要组成部分.
相关概念视频
Coronary Artery Disease V: Interprofessional Care
343
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
343
Peripheral Artery Disease III: Interprofessional Care
433
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
433
Atherosclerosis III: Management
512
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
512
Aneurysm III: Interprofessional Care
387
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
387
Aortic Regurgitation III: Medical Management
512
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
512


